Representatives of the electronic cigarette industry expressed dissatisfaction with the plan announced by the US Food and Drug Administration (FDA) on February 24 to address deficiencies in its Center for Tobacco Products (CTP) operations.
The negative feedback emerged collectively after the FDA released its new 5-year strategic plan for the Center for Tobacco Products (CTP), which seemed more like an anger directed at its slow past management.
For example, public health advocates are urging the Center for Tobacco Products to more actively regulate regular cigarettes and flavored e-liquids, while tobacco companies complain that the FDA is unwilling to approve new products, including e-cigarettes, designed to help adults quit smoking.
To understand the public or electronic cigarette industry's dissatisfaction with CTP, we must look at the "five-year strategic plan" that CTP launched in response to criticism from the Reagan-Udall group.
In December 2022, Reagan-Udall evaluators stated that the FDA was "slow to react and overwhelmed," with low employee morale and struggling to regulate both traditional tobacco products and the rapidly expanding e-cigarette market. This prompted a review within the CTP and ultimately led to the creation of a "five-year strategic plan.
At the beginning of the program, CTP openly admitted to previously being slow to react. However, in order to address current challenges and position itself for the future, CTP must shift from a passive to an active approach.
These measures aim to improve the negative perception of CTP through six areas, including cross-disciplinary collaboration, scientific and application review, regulation and guidance, compliance and enforcement, public education activities, and resources. The 15 individual measures correspond to the 15 recommendations put forward by the Reagan-Udall group.
Returning to the concerns of the e-cigarette industry association and manufacturers, the focus is on compliance and enforcement, as well as scientific and application reviews. Of particular interest is the PMTA, which is at the center of external attention. The "five-year strategic plan" includes internal efforts and better communication with external stakeholders on scientific issues and practices to support efficiency, effectiveness, and transparency. Additional staff will be hired to strengthen project management and implementation, including application reviews. Internal communication will be improved to improve mechanisms for scientific engagement and deliberation.
However, these measures have not answered or resolved the most pressing concerns of the electronic cigarette industry. The industry generally believes that "the current application review process is very cumbersome and time-consuming, with unclear and often changing submission requirements, which may have an adverse effect on manufacturers' innovation capabilities and compliance with submission deadlines.
The head of the Vapor Technology Association, Tony Abboud, believes that the FDA's statement does not indicate any improvement in its hostile attitude towards nicotine-containing products.
Representatives of the electronic cigarette industry have expressed disappointment with the FDA's statement, stating that this will continue to result in the majority of electronic cigarette products being rejected by the FDA.
The US Electronic Cigarette Manufacturers Association stated in a declaration that the FDA's Center for Tobacco Products (CTP) should apologize to the American public for its efforts to suppress the nicotine e-cigarette market following the Reagan-Udall report, which caused great harm.
References:
The vaping industry is not impressed with the "reset" by the Center for Tobacco Products.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
